PT  - JOURNAL ARTICLE
AU  - Parker, Edward P. K.
AU  - Bronowski, Christina
AU  - Sindhu, Kulandaipalayam Natarajan C.
AU  - Babji, Sudhir
AU  - Benny, Blossom
AU  - Carmona-Vicente, Noelia
AU  - Chasweka, Nedson
AU  - Chinyama, End
AU  - Cunliffe, Nigel A.
AU  - Dube, Queen
AU  - Giri, Sidhartha
AU  - Grassly, Nicholas C.
AU  - Gunasekaran, Annai
AU  - Howarth, Deborah
AU  - Immanuel, Sushil
AU  - Jere, Khuzwayo C.
AU  - Kampmann, Beate
AU  - Lowe, Jenna
AU  - Mandolo, Jonathan
AU  - Praharaj, Ira
AU  - Rani, Bakthavatsalam Sandya
AU  - Silas, Sophia
AU  - Srinivasan, Vivek Kumar
AU  - Turner, Mark
AU  - Venugopal, Srinivasan
AU  - Verghese, Valsan Philip
AU  - Darby, Alistair C.
AU  - Kang, Gagandeep
AU  - Iturriza-Gómara, Miren
TI  - Impact of maternal antibodies and microbiota development on the immunogenicity of oral rotavirus vaccine in African, Indian, and European infants: a prospective cohort study
AID  - 10.1101/2020.11.02.20224576
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.11.02.20224576
4099  - http://medrxiv.org/content/early/2020/12/11/2020.11.02.20224576.short
4100  - http://medrxiv.org/content/early/2020/12/11/2020.11.02.20224576.full
AB  - Identifying risk factors for impaired oral rotavirus vaccine (ORV) efficacy in low-income countries may lead to improvements in vaccine design and delivery. We measured maternal rotavirus antibodies, environmental enteric dysfunction (EED), and bacterial gut microbiota development among infants receiving two doses of Rotarix in India (n = 307), Malawi (n = 119), and the UK (n = 60), using standardised methods across cohorts. ORV shedding and seroconversion rates were significantly lower in Malawi and India than the UK. Maternal rotavirus-specific antibodies in serum and breastmilk were negatively correlated with ORV response in India and Malawi, and this was mediated partly by a reduction in ORV replication. In the UK, ORV replication was not inhibited despite comparable maternal antibody levels. In both India and Malawi, pre-vaccination microbiota diversity was negatively correlated with ORV immunogenicity, suggesting that high early-life microbial exposure may contribute to impaired vaccine efficacy.Competing Interest StatementM.I.G. has received research grants from GSK and Merck, and has provided expert advice to GSK. K.C.J. and N.A.C. have received investigator-initiated research grant support from GSK. N.A.C. has received research grant support and honoraria for participation in rotavirus vaccine data safety monitoring committee meetings from GSK.Clinical TrialCTRI/2015/11/006354Clinical Protocols https://bmjopen.bmj.com/content/7/3/e016577.long Funding StatementThe UK and Malawi sites were funded by the UK Medical Research Council and the UK Department for International Development (Newton Fund MR/N006259/1). M.I.G. is partly supported by the NIHR HPRU in Gastrointestinal Infections. K.C.J. is funded by a Wellcome International Training Fellowship (number 201945/Z/16/Z). The site in India was funded by the Government of India's Department of Biotechnology.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board at the Christian Medical College (CMC) in Vellore, the College of Medicine Research and Ethics Committee in Blantyre, and the North West - Liverpool East Research Ethics Committee in Liverpool.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw sequence data generated during this study have been deposited in the European Nucleotide Archive (accession number PRJEB38948). Processed data and analysis code generated during this study are available on github (https://github.com/eparker12/RoVI). https://github.com/eparker12/RoVI